bluebird bio, Inc. (BLUE) Rating Reiterated by Jefferies Group LLC
bluebird bio, Inc. (NASDAQ:BLUE)‘s stock had its “hold” rating restated by analysts at Jefferies Group LLC in a research note issued on Friday. They presently have a $130.00 price target on the biotechnology company’s stock. Jefferies Group LLC’s target price points to a potential downside of 15.61% from the stock’s previous close. Jefferies Group also issued estimates for bluebird bio’s FY2021 earnings at $4.38 EPS.
A number of other equities analysts have also weighed in on the stock. Morgan Stanley upgraded shares of bluebird bio from an “underweight” rating to an “equal weight” rating in a research report on Friday. Barclays PLC increased their target price on shares of bluebird bio from $151.00 to $162.00 and gave the stock an “overweight” rating in a research report on Thursday. Maxim Group reiterated a “buy” rating and set a $170.00 target price on shares of bluebird bio in a research report on Thursday. Wedbush reiterated an “outperform” rating and set a $174.00 target price (up previously from $135.00) on shares of bluebird bio in a research report on Thursday. Finally, BTIG Research upgraded shares of bluebird bio from a “neutral” rating to a “buy” rating and set a $177.00 target price for the company in a research report on Thursday. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $129.45.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). The business had revenue of $7.71 million for the quarter, compared to the consensus estimate of $8.47 million. bluebird bio had a negative return on equity of 30.14% and a negative net margin of 883.18%. bluebird bio’s revenue for the quarter was up 397.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($2.07) EPS.
In other news, insider Nick Leschly sold 7,050 shares of the stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $145.14, for a total transaction of $1,023,237.00. Following the completion of the transaction, the insider now directly owns 259,059 shares in the company, valued at approximately $37,599,823.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James Mandell sold 1,000 shares of the stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $95.95, for a total value of $95,950.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at $95,950. The disclosure for this sale can be found here. Insiders sold a total of 149,141 shares of company stock valued at $18,759,547 over the last 90 days. 3.90% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Quantitative Investment Management LLC boosted its position in shares of bluebird bio by 1,193.8% during the 2nd quarter. Quantitative Investment Management LLC now owns 104,800 shares of the biotechnology company’s stock valued at $11,009,000 after acquiring an additional 96,700 shares during the last quarter. State of Wisconsin Investment Board bought a new position in shares of bluebird bio during the 2nd quarter valued at approximately $3,257,000. Winfield Associates Inc. boosted its position in shares of bluebird bio by 6.1% during the 2nd quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock valued at $296,000 after acquiring an additional 162 shares during the last quarter. OMERS ADMINISTRATION Corp bought a new position in shares of bluebird bio during the 2nd quarter valued at approximately $1,061,000. Finally, Northern Trust Corp boosted its position in shares of bluebird bio by 11.7% during the 2nd quarter. Northern Trust Corp now owns 518,673 shares of the biotechnology company’s stock valued at $54,487,000 after acquiring an additional 54,142 shares during the last quarter.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.